PRAGUE-12 trial: Randomized open multicenter study

August 28, 2012

The PRAGUE-12 trial is a randomized open multicenter study comparing cardiac surgery with MAZE versus cardiac surgery without MAZE in patients with coronary and/or valvular heart disease and with atrial fibrillation.

Surgical ablation of the to restore regular sinus rhythm is widely used in patients with atrial fibrillation (AF) undergoing . The restoration of sinus rhythm might decrease the risk of heart failure, stroke and death during long-term follow up.(1) However, despite its promise, this theoretical benefit has never been clearly established - previous randomised studies have been small and performed in a selected group of patients undergoing .

Now, a multicentre study of surgical ablation (using the MAZE procedure) organised by and cardiac surgeons at the Cardiocenter in Prague, Czech Republic, has assessed its long-term impact in patients with AF referred for cardiac surgery (for /repair, or combined surgery). The study tested the hypothesis that the MAZE procedure would increase sinus rhythm prevalence one year after surgery without increasing peri-procedural complications, and possibly improve the long-term (mortality, heart failure, stroke, bleeding).

Results of the study, presented here today by Professor Petr Widimsky from the Cardiocenter of Charles University, Prague, first confirmed that the MAZE procedure performed during cardiac surgery does indeed improve the likelihood of sinus rhythm presence one year post-operatively. However, said Professor Widimsky, this effect was significant only among patients with permanent pre-operative AF. Further results also showed that the MAZE procedure had a neutral effect (neither negative nor positive) on mortality, stroke or other hard clinical end-points during one year follow up.

The primary efficacy outcome of the study was the presence of sinus rhythm (with no episode of atrial fibrillation) during 24-hour ECG monitoring one year after surgery. The primary safety outcome was the combined endpoint of death/myocardial infarction/stroke or transient ischemic attack/new onset renal failure requiring hemodialysis at 30 days.

Secondary outcomes were individual components of the primary safety outcome registered after one year, bleeding complications, heart failure, use of anticoagulation at one year, use of antiarhythmis drugs at one year, pacemaker or cardioverter implantation, and catheter .

Detailed results showed that the MAZE procedure prolonged total surgical time by 20 minutes (220 min. MAZE vs. 200 min. no-MAZE). Holter monitoring one year after surgery revealed sinus rhythm without any AF episodes in 60.2% of MAZE patients vs. 35.5% of the no-MAZE group (p=0.002). The combined safety endpoint (MACE) at 30 days was positive in 10.3% MAZE vs. 14.7% no-MAZE (not significant). There was no change in either the left ventricular ejection fraction or in the left atrial diameter. All-cause one year mortality was 16.2% in the MAZE group and 17.4% in the no-MAZE group (not significant). Stroke occurred in 2.7% MAZE vs. 4.3% no-MAZE (p=0.319).

There was a slight trend towards more hospitalisations for during one year among non-MAZE patients (26.1%) than among MAZE 23.4% (p=0.680). Major bleeding occurred in 9.9% MAZE vs. 9.8% non-MAZE (p=0.654).

When patients were divided into subgroups based on AF type at randomisation, there was no difference between the MAZE and non-MAZE groups in the presence of sinus rhythm at one year among paroxysmal or persistent AF patients. There was, however, a highly significant increase in sinus rhythm restoration rate among patients with permanent AF treated by MAZE at one year (53.2% vs. 13.9%, p<0.001). The number of true responders (that is, the percentage of patients who had AF at the time of surgery and sinus rhythm at one year) was 56% MAZE vs. 17% non-MAZE (p=0.000029).

Explore further: New procedure treats atrial fibrillation

More information: 1. The MAZE procedure is a surgical treatment of atrial fibrillation in which several incisions are made on the left and right atriums of the heart to form scar tissue. The scar tissue inhibits the transmission of electrical signals, thereby reducing the incidence of the arrhythmia.

Related Stories

New procedure treats atrial fibrillation

June 28, 2011
Doctors at Washington University School of Medicine in St. Louis are performing a new procedure to treat atrial fibrillation, a common irregular heartbeat.

Study suggests atrial fibrillation should be surgically treated when performing cardiac surgery

April 26, 2012
A recent study conducted by Northwestern Medicine® researchers published in the Journal of Thoracic and Cardiovascular Surgery, reveals that patients with an abnormal heart rhythm known as atrial fibrillation (A-fib) ...

Atrial fibrillation may be root cause of some severe mitral regurgitation cases

September 22, 2011
Mitral regurgitation is a common heart valve disorder, where blood flows backwards through the mitral valve when the heart contracts and reduces the amount of blood that is pumped out to the body. It is a serious condition ...

The big risk factor for stroke that you may not know you have

September 15, 2011
A cardiac condition called atrial fibrillation, the most common cardiac arrhythmia, can increase your risk of stroke by 500 percent. That's why Anne B. Curtis, MD, Charles and Mary Bauer Professor and Chair of the University ...

Recommended for you

Early study shows shoe attachment can help stroke patients improve their gait

December 14, 2017
A new device created at the University of South Florida – and including a cross-disciplinary team of experts from USF engineering, physical therapy and neurology – is showing early promise for helping correct the signature ...

Scientists rewrite our understanding of how arteries mend

December 13, 2017
Scientists from The University of Manchester have discovered how the severity of trauma to arterial blood vessels governs how the body repairs itself.

Deadly heart rhythm halted by noninvasive radiation therapy

December 13, 2017
Radiation therapy often is used to treat cancer patients. Now, doctors at Washington University School of Medicine in St. Louis have shown that radiation therapy—aimed directly at the heart—can be used to treat patients ...

Ultra-thin tissue samples could help to understand and treat heart disease

December 12, 2017
A new method for preparing ultra-thin slices of heart tissue in the lab could help scientists to study how cells behave inside a beating heart.

Young diabetics could have seven times higher risk for sudden cardiac death

December 12, 2017
Young diabetics could have seven times more risk of dying from sudden cardiac arrest than their peers who don't have diabetes, according to new research.

Research reveals how diabetes in pregnancy affects baby's heart

December 12, 2017
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered how high glucose levels—whether caused by diabetes or other factors—keep heart cells from maturing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.